In this context, Xiao et al. [127] investigated the regulatory effect of the histone deacetylase (HDAC) inhibitor drug MS-275 on hepatoma cell-derived ExVs, MICA and MICB. The gene discussed is MICB; the disease is hepatocellular carcinoma.